Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hind Rafei

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|July 23, 2024
Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignanciesHind Rafei, Katayoun Rezvani
British Journal of Haematology|December 2, 2024
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancerHind Rafei, Katayoun Rezvani
Best Practice & Research. Clinical Haematology|June 18, 2019
Hereditary myeloid malignanciesHind Rafei, Courtney D DiNardo
Blood|June 12, 2020
Microbiome-intestine cross talk during acute graft-versus-host diseaseHind Rafei, Robert R Jenq
Pulmonary Circulation|June 24, 2017
Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertensionArun Jose, Hind Rafei, Jalil Ahari
Nature Reviews. Immunology|July 2, 2026
A guide to CAR T cell therapies: development, current status and future prospectsHind Rafei, Ranjan Upadhyay, Padmanee Sharma
Cureus|June 6, 2017
Post-Transfusion Purpura: A Case Report of an Underdiagnosed PhenomenonHind Rafei, Raza Yunus, Samah Nassereddine
Immunological Reviews|August 7, 2023
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancerYe Li, Katayoun Rezvani, Hind Rafei
Hematology/Oncology and Stem Cell Therapy|May 28, 2017
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapiesHind Rafei, Mohamed A Kharfan-Dabaja
British Journal of Haematology|November 20, 2020
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunityHind Rafei, May Daher, Katayoun Rezvani
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|July 23, 2024
Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignanciesHind Rafei, Katayoun Rezvani
British Journal of Haematology|December 2, 2024
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancerHind Rafei, Katayoun Rezvani
Best Practice & Research. Clinical Haematology|June 18, 2019
Hereditary myeloid malignanciesHind Rafei, Courtney D DiNardo
Blood|June 12, 2020
Microbiome-intestine cross talk during acute graft-versus-host diseaseHind Rafei, Robert R Jenq
Pulmonary Circulation|June 24, 2017
Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertensionArun Jose, Hind Rafei, Jalil Ahari
Nature Reviews. Immunology|July 2, 2026
A guide to CAR T cell therapies: development, current status and future prospectsHind Rafei, Ranjan Upadhyay, Padmanee Sharma
Cureus|June 6, 2017
Post-Transfusion Purpura: A Case Report of an Underdiagnosed PhenomenonHind Rafei, Raza Yunus, Samah Nassereddine
Immunological Reviews|August 7, 2023
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancerYe Li, Katayoun Rezvani, Hind Rafei
Hematology/Oncology and Stem Cell Therapy|May 28, 2017
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapiesHind Rafei, Mohamed A Kharfan-Dabaja
British Journal of Haematology|November 20, 2020
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunityHind Rafei, May Daher, Katayoun Rezvani
Pageof 6